View Exam | PowerPak

1. The Centers for Disease Control and Prevention (CDC) has released the Preexposure Prophylaxis for the Prevention of HIV Infection in the United States—2021 Update—A Clinical Practice Guideline. Which assessment is NOT part of the CDC revised practice recommendations for patients taking oral PrEP:

A. Assess creatinine clearance (frequency may vary based on patient age) B. For patients taking only F/TAF, measure the patients' triglyceride, cholesterol levels and weight annually C. Bone mineral density tests, DEXA scans or other assessments of bone health. D. Review the list of medications that may interact with patients on F/TAF or F/TDF (polypharmacy).

2. For injectable PrEP (Cabotegravir), the updated CDC practice guidelines also include a new section that details the ongoing assessments and follow-up schedule for patients taking CAB. As a provider, which guideline is no longer applicable?

A. Regular kidney, triglyceride, or cholesterol assessments are not needed for patients taking CAB, as they are for patients taking oral PrEP. B. Providers must repeat sexual behavior risk assessments prior to or during each injection visit. C. HIV testing every 2 months (at each injection visit). D. Sexually transmitted infection (STI) testing every 4 months (at every other injection visit).

3. Non-grandfathered plans and issuers may use reasonable medical management techniques (UM) to encourage individuals prescribed PrEP to use specific items and services. And while both F/TDF and F/TAF are FDA approved for use as PrEP, health plans may not list all agents (generic or brand name) as preferred for use. Which of the following reasonable medical management techniques is permissible?

A. Plans and issuers may use reasonable medical management techniques to the extent the frequency, method, treatment, or setting is not specified in the USPSTF recommendation. B. Plans and issuers may use reasonable medical management techniques to the extent the frequency, method, treatment, or setting is specified in the USPSTF recommendation. C. Plans and issuers are not authorized to use reasonable medical management techniques when prescribing PrEP. D. Plans and issuers do not need to accommodate any individual for whom a particular PrEP medication (generic or brand name) would be medically inappropriate.

4. If your patient's non-grandfathered health plan or issuer is utilizing reasonable medical management techniques (UM), they must allow exceptions to UM policy. Which statement is also true?

A. Plans and issuers must have an easily accessible and transparent exceptions process, but it can be complicated to access. B. Plans and issuers must have an easily accessible, transparent, and sufficiently expedient exceptions process that is not unduly burdensome. C. Plans and issuers must consult with the prescriber prior to adjudicating on any exception to policy. D. Plans and issuers are not permitted to use reasonable medical management techniques on PrEP.

5. Community pharmacists are essential to a person's interdisciplinary care team and can significantly contribute to better health outcomes. One of your MSM patients, Tim, recently started daily oral PrEP with his primary care provider (PCP). After the initial visit and prescription fill, Tim comes back into your pharmacy and asks to speak to you about some required follow-up care. Tim explains that his PCP won't refill Tim's next 90-day PrEP prescription until he has another office visit, despite reporting 100% adherence and no adverse drug reactions/interactions. Which one of the following is an approach to that follow-up care?

A. Monitoring adherence and HIV/STI screening and testing isn't necessary after the initial prescription fill. B. Once all initial HIV and STI screenings are complete, refill authorizations for daily oral PrEP for more than 90 days. C. Monitoring adherence to PrEP can identify those at-risk becoming lost to follow-up and at greater risk of HIV infection. D. Gaps in the PrEP care continuum aren't as concentrated in MSM populations, so follow-up isn't necessary.

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

2. For injectable PrEP (Cabotegravir), the updated CDC practice guidelines also include a new section that details the ongoing assessments and follow-up schedule for patients taking CAB. As a provider, which guideline is no longer applicable?

4. If your patient's non-grandfathered health plan or issuer is utilizing reasonable medical management techniques (UM), they must allow exceptions to UM policy. Which statement is also true?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

2. For injectable PrEP (Cabotegravir), the updated CDC practice guidelines also include a new section that details the ongoing assessments and follow-up schedule for patients taking CAB. As a provider, which guideline is no longer applicable?

4. If your patient's non-grandfathered health plan or issuer is utilizing reasonable medical management techniques (UM), they must allow exceptions to UM policy. Which statement is also true?

« Return to Activity

Customers who Purchased
this Activity also Purchased